American Association for Cancer Research
23266066cir180386-sup-203394_3_supp_5482377_pqjvbl.pdf (224.95 kB)

Supplementary Figure 2 from Anti–CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control

Download (224.95 kB)
journal contribution
posted on 2023-04-03, 23:26 authored by Emilio Sanseviero, Erin M. O’Brien, Jenna R. Karras, Tamer B. Shabaneh, Bulent Arman Aksoy, Wei Xu, Cathy Zheng, Xiangfan Yin, Xiaowei Xu, Giorgos C. Karakousis, Ravi K. Amaravadi, Brian Nam, Mary Jo Turk, Jeff Hammerbacher, Mark P. Rubinstein, Lynn M. Schuchter, Tara C. Mitchell, Qin Liu, Erica L. Stone

Supplementary Figure 2


Bristol-Myers Squibb-MRA Young Investigator Award


BNY Mellon

Emerson Collective

Cancer Center Support





Antibodies targeting CTLA-4 induce durable responses in some patients with melanoma and are being tested in a variety of human cancers. However, these therapies are ineffective for a majority of patients across tumor types. Further understanding the immune alterations induced by these therapies may enable the development of novel strategies to enhance tumor control and biomarkers to identify patients most likely to respond. In several murine models, including colon26, MC38, CT26, and B16 tumors cotreated with GVAX, anti–CTLA-4 efficacy depends on interactions between the Fc region of CTLA-4 antibodies and Fc receptors (FcR). Anti–CTLA-4 binding to FcRs has been linked to depletion of intratumoral T regulatory cells (Treg). In agreement with previous studies, we found that Tregs infiltrating CT26, B16-F1, and autochthonous BrafV600EPten−/− melanoma tumors had higher expression of surface CTLA-4 (sCTLA-4) than other T-cell subsets, and anti–CTLA-4 treatment led to FcR-dependent depletion of Tregs infiltrating CT26 tumors. This Treg depletion coincided with activation and degranulation of intratumoral natural killer cells. Similarly, in non–small cell lung cancer (NSCLC) and melanoma patient-derived tumor tissue, Tregs had higher sCTLA-4 expression than other intratumoral T-cell subsets, and Tregs infiltrating NSCLC expressed more sCTLA-4 than circulating Tregs. Patients with cutaneous melanoma who benefited from ipilimumab, a mAb targeting CTLA-4, had higher intratumoral CD56 expression, compared with patients who received little to no benefit from this therapy. Furthermore, using the murine CT26 model we found that combination therapy with anti–CTLA-4 plus IL15/IL15Rα complexes enhanced tumor control compared with either monotherapy.

Usage metrics

    Cancer Immunology Research



    Ref. manager